Latest Earnings Results: Q1 '26
Estimated EPS
-$0.20
Reported EPS
-$0.27
Surprise
-33.66%
Estimated Rev
$0.49M
Reported Rev
---
Surprise
---
OS Therapies reported a net loss of $19.0 million for the six months ended June 30, 2026, with research and development expenses totaling $13.4 million during the same period.
Bullish Takeaway
OS Therapies achieved statistically significant survival benefits in its Phase IIb clinical trial and strengthened its liquidity position through successful equity and debt financing initiatives during the current period.
Bearish Takeaway
OS Therapies faces substantial doubt regarding its ability to continue as a going concern, while restrictive debt covenants and ineffective internal financial controls further constrain the operations of OS Therapies.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.18 | -- | -- | N/A |
Q1 '26 | -$0.20 | -$0.27 | -33.66% | MISSED |
Q4 '25 | -$0.25 | -- | -- | N/A |
Q3 '25 | -$0.16 | -$0.21 | -31.25% | MISSED |
Q2 '25 | -$0.19 | -$0.19 | -2.70% | MISSED |